Poehling Capital Management INC. Lowers Position in Organon & Co. $OGN

Poehling Capital Management INC. decreased its holdings in shares of Organon & Co. (NYSE:OGN) by 31.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 216,492 shares of the company’s stock after selling 101,256 shares during the period. Poehling Capital Management INC.’s holdings in Organon & Co. were worth $1,552,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Amalgamated Bank increased its stake in shares of Organon & Co. by 1.9% during the third quarter. Amalgamated Bank now owns 79,805 shares of the company’s stock valued at $852,000 after purchasing an additional 1,514 shares in the last quarter. State of Alaska Department of Revenue increased its stake in shares of Organon & Co. by 0.6% during the fourth quarter. State of Alaska Department of Revenue now owns 278,379 shares of the company’s stock valued at $1,995,000 after purchasing an additional 1,570 shares in the last quarter. Integrated Wealth Concepts LLC increased its stake in shares of Organon & Co. by 2.8% during the third quarter. Integrated Wealth Concepts LLC now owns 58,648 shares of the company’s stock valued at $626,000 after purchasing an additional 1,594 shares in the last quarter. Arizona State Retirement System increased its stake in shares of Organon & Co. by 2.2% during the third quarter. Arizona State Retirement System now owns 76,924 shares of the company’s stock valued at $822,000 after purchasing an additional 1,644 shares in the last quarter. Finally, Rothschild Investment LLC increased its stake in shares of Organon & Co. by 73.1% during the third quarter. Rothschild Investment LLC now owns 3,899 shares of the company’s stock valued at $42,000 after purchasing an additional 1,646 shares in the last quarter. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Price Performance

Shares of OGN opened at $13.44 on Wednesday. The company has a market capitalization of $3.53 billion, a P/E ratio of 14.45, a price-to-earnings-growth ratio of 1.24 and a beta of 1.57. The company has a quick ratio of 1.42, a current ratio of 1.97 and a debt-to-equity ratio of 9.47. The firm has a 50 day moving average of $9.02 and a 200 day moving average of $8.11. Organon & Co. has a twelve month low of $5.69 and a twelve month high of $13.47.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings results on Thursday, April 30th. The company reported $0.71 earnings per share for the quarter, missing the consensus estimate of $0.83 by ($0.12). The firm had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.49 billion. Organon & Co. had a net margin of 3.99% and a return on equity of 99.95%. Organon & Co.’s revenue was down 3.5% on a year-over-year basis. During the same period last year, the business earned $1.02 EPS. As a group, equities research analysts anticipate that Organon & Co. will post 3.23 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 11th. Shareholders of record on Monday, May 11th will be given a $0.02 dividend. This represents a $0.08 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Monday, May 11th. Organon & Co.’s payout ratio is 8.60%.

Insider Buying and Selling

In related news, SVP Lynette Holzbaur bought 26,448 shares of the business’s stock in a transaction on Wednesday, May 6th. The stock was acquired at an average price of $13.35 per share, with a total value of $353,080.80. Following the transaction, the senior vice president owned 52,851 shares in the company, valued at approximately $705,560.85. This trade represents a 100.17% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 1.62% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Barclays raised their target price on shares of Organon & Co. from $7.50 to $8.00 and gave the company an “underweight” rating in a research note on Tuesday, February 24th. Zacks Research raised shares of Organon & Co. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 14th. Piper Sandler raised shares of Organon & Co. from an “underweight” rating to a “neutral” rating and raised their price target for the company from $5.00 to $14.00 in a research report on Tuesday, April 28th. Wall Street Zen downgraded shares of Organon & Co. from a “buy” rating to a “hold” rating in a research report on Saturday, January 31st. Finally, Weiss Ratings raised shares of Organon & Co. from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday. Five equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus price target of $11.40.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.